Motility-related protein-1 (MRP-1/CD9) is a transmembrane glycoprotein that has been implicated in cell adhesion, motility, proliferation, and differentiation. It has a functional role as a tumor metastatic suppressor. During tumor progression, a reduction of MRP-1/CD9 gene expression results in tumor cells with a high metastatic potential. However, the mechanism of action of MRP-1/CD9 is still unclear. We studied changes of gene expression in relation to MRP-1/CD9 gene transduction into tumor cell lines, HT1080 and A549, using microarray assays and real-time PCR. Consequently, we have demonstrated that MRP-1/ CD9 gene transduction can downregulate expression of several Wnt family genes, such as Wnt1, Wnt2b1 and Wnt5a, and their target genes, including WISP-1 (Wnt-1 induced secreted protein 1), WISP-3, c-Myc, vascular endothelial growth factor-A, and matrix metalloproteinase-26. Western blot analyses also showed that MRP-1/CD9 gene transduction downregulated expression of Wnt1 protein and its target proteins. In addition, a neutralizing anti-MRP-1/CD9 monoclonal antibody inhibited the downregulation of Wnt signal pathways in MRP-1/CD9-transfected cells. The present study has revealed that the MRP-1/CD9 signal is located upstream of the Wnt signal pathways. Therefore, MRP-1/CD9 could suppress cell transformation including epithelial to mesenchymal transition through downregulation of Wnt1, and might suppress tumor metastasis through downregulation of Wnt5a.
Introduction
Motility-related protein-1 (MRP-1/CD9) has been implicated in various biological functions, including cell adhesion, motility, proliferation, and differentiation (Ikeyama et al., 1993; Aoyama et al., 1999) . Regarding tumor progression, previous experimental and clinical studies have demonstrated that MRP-1/CD9 has a functional role as a tumor metastatic suppressor. Transfection with human MRP-1/CD9 cDNA revealed that cell motility was suppressed in MRP-1/CD9-expressing cells (Ikeyama et al., 1993) . In addition, transfection with human MRP-1/CD9 cDNA using adenoviral vectors also suppressed pulmonary metastasis in a spontaneous metastatic model using immunodeficient mice (Miyake et al., 2000) . Many clinical studies have revealed that reduced MRP-1/CD9 expression is associated with a poor prognosis in various cancers, including non-small-cell lung cancers, breast cancers, and colon cancers (Higashiyama et al., 1995; Huang et al., 1998; Mori et al., 1998) .
However, the biological mechanisms of MRP-1/CD9 are still not clearly understood. MRP-1/CD9 is a member of the transmembrane 4 superfamily (TM4SF), which are transmembrane glycoproteins forming functional complexes with integrins at the cell membrane. Therefore, MRP-1/CD9 is considered to have multiple biological functions through integrin signaling (Berditchevski and Odintsova, 1999) . Recent studies have found various signal pathways and cross-talk between them. To identify specific pathways associated with MRP-1/CD9, we performed a large-scale parallel gene expression analysis using microarray assays and subsequent real-time quantitative reverse transcription-PCR (RT-PCR). We then performed Western blot analysis to evaluate protein expression. Consequently, we have demonstrated that MRP-1/CD9 gene transduction downregulates Wnt signal pathways, including several Wnt family genes and their target genes.
Results
Transfection using rAd5CAG-MRP-1/CD9 can restore MRP-1/CD9 expression We used two cell lines, the human fibrosarcoma cell line HT1080 and the human lung adenocarcinoma cell line A549. At first, in order to evaluate MRP-1/CD9 gene expression in HT1080 and A549, real-time quantitative RT-PCR was performed. The comparative threshold cycle method (Applied Biosystems, Foster City, CA, USA) was used to determine the MRP-1/CD9 gene conservation rates, gene expression in each cell line relative to the value observed in the human lung adenocarcinoma cell MAC10 (positive control), using GAPDH as normalization controls. The MRP-1/CD9 gene conservation rates were found to be 1.2% in HT1080 (MRP-1/CD9 negative) and 54.2% in A549 (MRP-1/CD9 reduced).
An E1-deleted replication-deficient recombinant adenoviral vector encoding human MRP-1/CD9 (rAd5-CAG-MRP-1/CD9) under the control of the human CAG promoter was constructed using an Adenovirus Expression Vector kit (Takara Biomedicals, Otsu, Japan) (Miyake et al., 2000) . In addition, an E1-deleted replication-deficient control adenovirus containing the bacterial lacZ gene (rAd5CAG-LacZ) under the control of the human CAG promoter was also constructed.
At 3 days after transfection of MRP-1/CD9 into HT1080 and A549 using rAd5CAG-MRP-1/CD9, we performed real-time quantitative RT-PCR analysis to measure MRP-1/CD9 gene expression, Western blot analysis and flow cytometric assays for MRP-1/CD9 protein expression, on each group of cells; cells after treatment with rAd5CAG-MRP-1/CD9 (CD9-HT1080 and CD9-A549), cells after treatment with a control vector rAd5CAG-LacZ (LacZ-HT1080 and LacZ-A549), and untreated control cells (HT1080 and A549).
Real-time quantitative RT-PCR demonstrated that transfection using rAd5CAG-MRP-1/CD9 induced upregulation of MRP-1/CD9 gene expression both in HT1080 and in A549. MRP-1/CD9 gene expression was upregulated in CD9-HT1080 as compared with HT1080 (94.671.6-fold), and the MRP-1/CD9 gene conservation rate in CD9-HT1080 was increased to 113.5%. In contrast, there was no change in the MRP-1/CD9 gene conservation rate between LacZ-HT1080 and HT1080 (1.2 vs 1.2%). MRP-1/CD9 gene expression was also upregulated in CD9-A549 as compared with A549 (5.72570.113-fold), and the MRP-1/CD9 gene conservation rate in CD9-A549 was increased to 310.3%. In contrast, there was no change in the MRP-1/CD9 gene conservation rate between LacZ-A549 and A549 (48.3 vs 54.2%).
Following the real-time quantitative RT-PCR analysis, Western blot analysis and flow cytometric assays were performed to evaluate MRP-1/CD9 protein expression in each sample. Western blotting with monoclonal antibody (mAb) M31-15 demonstrated two bands of MRP-1/CD9, as reported previously (Miyake et al., 1991) . MRP-1/CD9 protein expression was upregulated in CD9-HT1080 as compared with HT-1080, and in CD9-A549 as compared with A549, both in Western blot analysis ( Figure 1 ) and flow cytometric assays (data not shown). In contrast, there was no change in MRP-1/CD9 protein expression between LacZ-HT1080 and HT1080, nor between LacZ-A549 and A549. Thus, transfection using rAd5CAG-MRP-1/ CD9 can restore gene and protein expression of MRP-1/ CD9 in HT1080 and A549 cells.
Transduction of the MRP-1/CD9 gene into HT1080 and A549 suppress their motility
To estimate the biological function of MRP-1/CD9 in cell motility, we performed motility assays and invasion assays using Transwell plates. In motility assays, numbers of cells passing through the membrane into the lower chamber were significantly smaller in CD9-HT1080 than in HT1080 (83.379.2 vs 141.378.5 at 6 h, P ¼ 0.0001; 163.578.2 vs 259.8721.7 at 12 h, P ¼ 0.0013) (Figure 2a) . Numbers of cells passing through the membrane into the lower chamber were also significantly smaller in CD9-A549 than in A549 (45.274.5 vs 71.877.8 at 36 h, P ¼ 0.0141; 47.372.9 vs 120.378.5 at 48 h, Po0.0001) (Figure 2b ).
Furthermore, in invasion assays using Transwell plates coated with Matrigel, numbers of cells migrating and attached to the lower side of the membrane were significantly smaller in CD9-HT1080 than in HT1080 (41.177.3 vs 86.7714.4 at 12 h, P ¼ 0.0183; 112.5713.3 vs 164.5711.1 at 24 h, P ¼ 0.0133) (Figure 2c ). Numbers of cells migrating and attached to the lower side of the membrane were also significantly smaller in CD9-A549 than in A549 (24.272.4 vs 40.375 .1 at 48 h, P ¼ 0.0168; 39.474.2 vs 58.974.3 at 72 h, P ¼ 0.0085) (Figure 2d ).
Microarray analyses have demonstrated that MRP-1/ CD9 gene transduction downregulates Wnt signal pathways
To clarify the biological roles of MRP-1/CD9, microarray analyses were performed using AceGene slides (DNA Chips Research Inc., Yokohama, Japan) spotted with 10368 cDNAs. Regarding gene expression related to signal pathways, the microarray analyses have demonstrated that several Wnt family genes and their target genes were downregulated in both CD9-HT1080 and CD9-A549 (Table 1) . Wnt1 (You et al., 2002) was downregulated in CD9-HT1080 as compared with HT1080 (0.060-fold), and in CD9-A549 as compared with A549 (0.413-fold); Wnt2b1 (Ricken et al., 2002) was also downregulated in both CD9-HT1080 (0.181-fold) and CD9-A549 (0.119-fold); In addition, Wnt5a (Weeraratna et al., 2002) was downregulated in both CD9-HT1080 (0.200-fold) and CD9-A549 (0.121-fold). However, there were no significant changes in gene expression of Wnt7a, Wnt11, and Wnt16. Of the target MRP-1/CD9 downregulates Wnt signal pathways C-l Huang et al genes of the Wnt family, WISP-1 (Wnt-1 induced secreted protein-1) (Pennica et al., 1998) was downregulated in both CD9-HT1080 (0.099-fold) and CD9-A549 (0.037-fold); and WISP-3 was also downregulated in both CD9-HT1080 (0.038-fold) and CD9-A549 (0.053-fold); In addition, c-Myc (He et al., 1998) was downregulated in both CD9-HT1080 (0.230-fold) and CD9-A549 (0.486-fold). Vascular endothelial growth factor-A (VEGF-A) (Zhang et al., 2001a) was downregulated in CD9-HT1080 (0.003-fold) and CD9-A549 (0.134-fold). Matrix metalloproteinase-26 (MMP-26) (Marchenko et al., 2002) was also downregulated in CD9-HT1080 (0.122-fold) and CD9-A549 (0.063-fold). However, the microarray assays have not shown significant findings in other signal pathways associated with cell motility, such as the phosphatidyl inositol signaling pathway (Vanhaesebroeck et al., 1999) , rho family (Ridley, 2001) , or MAP kinase pathways (Reddy et al., 2003) (Table 1 ). In addition, the microarray assays have not shown significant findings in cell-cycle regulators (Cordon-Cardo, 1995) .
Real-time PCR and Western blot analyses have confirmed that MRP-1/CD9 gene transduction downregulates Wnt signal pathways Next, real-time quantitative RT-PCR was performed to confirm the results of the above microarray assays. Simultaneously, transfection with rAd5CAG-LacZ was also performed as a control. Consequently, real-time PCR revealed that MRP-1/CD9 gene transduction can induce downregulation of these Wnt family genes and their target genes (Figure 3 ). Wnt1 was downregulated in CD9-HT1080 as compared with HT1080 (0.37870.027-fold), and in CD9-A549 as compared with A549 (0.54870.071-fold). Wnt2b1 was also downregulated in both CD9-HT1080 (0.39770.054-fold) and CD9-A549 (0.24670.033-fold). In addition, Wnt5a was downregulated in both CD9-HT1080 (0.26970.016-fold) and CD9-A549 (0.38770.076-fold). Concerning target genes of the Wnt family, WISP-1 was downregulated in both CD9-HT1080 (0.48670.051-fold) and CD9-A549 (0.51770.088-fold). WISP-3 was also downregulated in both CD9-HT1080 (0.05570.012-fold) and CD9-A549 (0.17270.042-fold). c-Myc was downregulated in both CD9-HT1080 (0.16370.032-fold) and CD9-A549 (0.45470.049-fold). VEGF-A was downregulated in CD9-HT1080 (0.27370.023-fold), but not in CD9-A549 (1.33170.155-fold). In addition, MMP-26 was downregulated in CD9-A549 (0.43570.028-fold), but not in CD9-HT1080 (0.80670.057-fold).
Furthermore, we performed Western blot analysis to evaluate the expression of these proteins. In the HT1080 cell line, MRP-1/CD9 gene transduction downregulated the protein expression of Wnt1, WISP-1, WISP-3, c-Myc, and VEGF-A (Figure 4a ). In the A549 cell line, MRP-1/CD9 gene transduction downregulated protein expression of Wnt1, WISP-1, WISP-3, and c-Myc, but not VEGF-A (Figure 4b ). In contrast, transfection with the control vector rAd5-CAG-LacZ did not affect protein expression of Wnt1, WISP-1, WISP-3, c-Myc, and VEGF-A in HT1080 or A549 cells. Western blot analyses also revealed that MRP-1/ CD9-transfected HT1080 cells maintained in media (Figure 4a ). In contrast, MRP-1/CD9-transfected HT1080 cells maintained in media containing a control mouse IgG had the same expression levels of these proteins as compared with CD9-HT1080. Furthermore, MRP-1/CD9-transfected A549 cells maintained in media containing ALB-6 also had an increased protein expression of Wnt1, WISP-1, WISP-3, and c-Myc, as compared with CD9-A549 (Figure 4b ). MRP-1/CD9-transfected A549 cells maintained in media containing a control mouse IgG had the same expression levels of these proteins as compared with CD9-A549. These results demonstrated that the neutralizing anti-MRP-1/CD9 mAb treatment inhibited the downregulation of Wnt signal pathways in MRP-1/CD9-transfected cells.
Discussion
MRP-1/CD9 has multiple biological functions, including cell adhesion, motility, proliferation, and differentiation (Ikeyama et al., 1993; Aoyama et al., 1999) . And these biological functions are considered to be associated with integrin signaling (Berditchevski and Odintsova, 1999 ). Because there are many possible ligands and various signal pathways, their precise mechanisms are not clearly understood. Previous experimental and clinical studies, however, have demonstrated that MRP-1/CD9 is involved in metastatic suppression. Therefore, we performed the present study to clarify the signal pathway of MRP-1/CD9, which might lead to new strategies of treatment for cancer patients. MRP-1/CD9 is considered to exert its biological functions by forming a functional complex with integrin a3b1 and integrin a6b1 (Zhang et al., 2001b; GutierrezLopez et al., 2003) . In fact, a previous clinical study has revealed that reduced integrin a3 expression is also a poor prognostic factors in patients with lung adenocarcinomas . Because HT080 and A549 cells have positive expression of both integrin a3 and integrin b1 (data not shown), these cell lines used in the present study are suitable for evaluating the biological functions of reduced MRP-1/CD9 expression. In addition, adenoviral vectors are involved in transient transfection, in which the induced DNA is not integrated into the host DNA. Therefore, adenoviral vectors are suitable for screening the signal pathway without the risk of disrupting the host genome. Consequently, we found that MRP-1/CD9 gene transduction could downregulate several members of the Wnt family, including Wnt1, Wnt2b1, and Wnt5a, and their target genes. Intriguingly, this transcriptional regulation from MRP-1/CD9 to the Wnt signal appeared both in the epithelial cell line A549 and in the nonepithelial cell line HT1080.
However, the microarray assays did not show significant findings in other signal pathways associated with cell motility, such as the phosphatidyl inositol signaling pathway (Vanhaesebroeck et al., 1999) , rho family (Ridley, 2001 ), or MAP kinase pathways (Reddy et al., 2003) . In addition, the microarray assays did not show significant findings in cell-cycle regulators (CordonCardo, 1995) . These results might be partly due to the fact that these signal pathways depend on protein phosphorylation, not transcriptional regulation. In fact, integrindependent signaling pathways are involved in the activation of phosphatidyl inositol 3-kinase (PI3-kinase) through integrin-linked kinase (ILK) (Chen et al., 1996; King et al., 1997) . In addition, recent studies have demonstrated that the Wnt signal also activates the phosphatidyl inositol signaling pathway (Slusarski et al., 1997) .
The Wnt gene family encode multi-functional signaling glycoproteins that are involved in the regulation of a wide variety of normal and pathological processes, including embryogenesis, epithelial differentiation, and tumorigenesis (Herzlinger et al., 1994; Dale, 1998; You et al., 2002) . They have been classified into two major functional groups with separate downstream signaling pathways. The Wnt1 class stimulates the canonical Wnt/ b-catenin signaling pathway, which leads to changes in cell fate and/or cell transformation (You et al., 2002) . Although the precise function of Wnt2b1 is still unknown, its paralog Wnt2 is also considered to be a member of the Wnt1 class (Katoh, 2003a) .
On the other hand, the Wnt5a class stimulates the Wnt/ Ca 2 þ signaling pathway, which modulates cell adhesion and cell motility. An experimental study using transfection of Wnt5a into melanoma cells has demonstrated that Wnt5a signaling directly affects actin reorganization resulting in actin ruffling and increased cell invasion (Weeraratna et al., 2002) . In addition, this study has shown that the aggressive sarcomatoid type of tumor cells showed a highly positive Wnt5a expression, while the epitheloid type of tumor cells showed lower levels of Wnt5a expression.
Thus, the Wnt gene family affects various biological behaviors of tumors, such as transformation, motility and invasion. In fact, upregulation of the Wnt family genes, including Wnt1 (Katoh, 2003b) , Wnt2b (Ricken et al., 2002) and Wnt5a (Saitoh et al., 2002) , has been reported to occur frequently in human cancers. The present study has demonstrated that MRP-1/CD9 gene transduction downregulates Wnt1 and Wnt5a both in HT1080 and in A549. These results suggested that MRP-1/CD9 could suppress cell transformation through downregulation of Wnt1, and might suppress tumor metastasis through downregulation of Wnt5a.
Furthermore, the present study has also revealed that MRP-1/CD9 downregulates many Wnt-target genes with TCF/LEF1 motifs (Korinek et al., 1997) , including WISP-1, WISP-3 (Pennica et al., 1998; Xu et al., 2000) , c-Myc (He et al., 1998) , VEGF-A (Zhang et al., 2001a) , and MMP-26 (Marchenko et al., 2002) . The Wnt gene family affects many biological functions through these target genes. Therefore, it is considered important to evaluate each target gene.
WISP-1 and WISP-3, members of the CCN family of growth factors, are upregulated in Wnt1-transformed cells, and they have been reported to be overexpressed in human colon tumors (Pennica et al., 1998) . WISP-1 is considered to play a role in tumor-stromal interaction (Desnoyers et al., 2001) , and overexpression of WISP-1 could induce morphological transformation and accelerated cell growth (Xu et al., 2000; You et al., 2002) . A previous clinical study on breast cancers has shown that overexpression of the WISP-1 gene is associated with more advanced features (Xie et al., 2001) . Therefore, downregulation of WISP-1 by MRP-1/CD9 gene transduction might lead to less aggressive tumor behavior. However, the exact biological function of WISP-3 is still unclear because it has also been reported to be a tumor suppressor gene (Kleer et al., 2002) . c-Myc is an oncogenic transcription factor that integrates the cell-cycle machinery, cellular metabolism, and the apoptotic pathways (Dang et al., 1999) . The expression of the c-Myc protein is frequently altered in human cancers, and overexpression of c-Myc is considered to promote neoplastic growth. Therefore, downregulation of c-Myc by MRP-1/CD9 gene transduction could also lead to less aggressive tumor behavior.
VEGF-A is a growth factor associated with angiogenesis (Dvorak et al., 1995) . Many previous studies have revealed that overexpression of VEGF-A is associated with tumor angiogenesis, nodal metastasis, and a poor prognosis in cancer patients (Masuya et al., 2001) . The present study has demonstrated that MRP-1/CD9 gene transduction could downregulate VEGF-A expression in HT1080. However, MRP-1/CD9 gene transduction did not induce downregulation of VEGF-A in A549, partly because A549 has a K-ras mutation, a potent positive regulator of VEGF-A (Mitchell et al., 1995) .
MMP-26 is also one of target genes of the Wnt family (Marchenko et al., 2002) . MMP-26 is widely expressed in cancer cells of epithelial origin (Marchenko et al., 2001) . It has a wide substrate specificity, and is able to activate MMP-9 (gelatinase B) which has been reported to affect tumor metastasis (Uria and Lopez-Otin, 2000) . Thus, MMP-26 plays an important role in tumor progression and metastasis. The present study has shown that MRP-1/CD9 gene transduction downregulates MMP-26 in A549. However, MRP-1/CD9 gene transduction did not affect MMP-26 gene expression in HT1080 because HT1080, a nonepithelial cell line, has a low expression level of MMP-26 initially.
On the other hand, cyclin D1 and CD44 are also reported to be target genes of the Wnt gene family (Tetsu and McCormick, 1999; Wielenga et al., 1999) . However, the present study has not shown any significant change in expression in either of these genes. These results might be partly explained by the choice of cell type in the present study, and partly due of the activity of other signal pathways, such as the Ras and ERK pathway for cyclin D1 regulation (Pruitt and Der, 2001; Jirmanova et al., 2002) , TGF-b and hepatocyte growth factor for CD44 regulation (Miyazaki et al., 2002; Mine et al., 2003) .
From these results, we have demonstrated that MRP-1/CD9 gene transduction could downregulate several Wnt family genes, including Wnt1 and Wnt5a, with a reduction of expression of their target genes. Furthermore, the present study has revealed that a neutralizing anti-MRP-1/CD9 mAb can inhibit the downregulation of the Wnt signal pathways in MRP-1/CD9-transfected cells. Therefore, it could be considered that the MRP-1/ CD9 signal is located upstream of the Wnt signal pathways. However, the molecular mechanisms of the interaction between MRP-1/CD9-associated integrin signaling and Wnt signaling are still not clear. ILK might play a role in the interaction of these molecules via protein phosphorylation, but not transcriptional regulation. Previous studies have shown that ILK regulates Wnt signaling in a PI3-kinase-dependent manner (D'Amico et al., 2000) . Thus, multidirectional cross-talk of signal pathways in tumor-stromal interactions would promote tumor progression. Further investigations should be performed to clarify the mechanism of Wnt gene regulation.
In contrast to the effect of MRP-1/CD9 transduction, the reduction of MRP-1/CD9 expression during tumor progression might cause the upregulation of Wnt family genes, resulting in aggressive tumor behavior, including epithelial to mesenchymal transformation, invasion, and metastasis. Knowledge of the mechanisms of tumor metastasis will lead to improvements in cancer therapies. The present study has demonstrated that MRP-1/CD9 and Wnt signaling play an important role in tumor progression. Therefore, new strategies, such as MRP-1/ CD9 gene therapy and soluble Frizzled-related proteins, could be rational treatments for cancer patients (Miyake et al., 2000; Roth et al., 2000) .
Materials and methods

Cell lines and cell culture
We used three cell lines, the human fibrosarcoma cell line HT1080, the human lung adenocarcinoma cell line A549, and the human lung adenocarcinoma cell line MAC10. The HT1080 and MAC10 lines were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum, and the A549 line was maintained in DMEM medium supplemented with 10% fetal calf serum.
Recombinant adenoviral vectors
An E1-deleted replication-deficient recombinant adenoviral vector encoding human MRP-1/CD9 (rAd5CAG-MRP-1/ CD9) under the control of the human CAG promoter was constructed using an Adenovirus Expression Vector kit (Takara Biomedicals) according to the manufacture's protocol. In addition, an E1-deleted replication-deficient control adenovirus containing the bacterial lacZ gene (rAd5CAG-LacZ) under the control of the human CAG promoter was also constructed. Adenovirus production was carried out using a 293 human embryonic kidney cell line, which provided the E1 protein in trans. Infectious titers measured in plaque-forming units (PFU/ ml) in adenovirus stocks or serum samples were determined by a limiting dilution bioassay using the 293 cell lines, and testing for replication competent adenovirus was subsequently performed.
Transfection
HT1080 and A549 were maintained in 10 cm culture dishes at 90% confluency. Infections with rAd5CAG-MRP-1/CD9 were performed at an MOI of 30 PFU/cell in a volume of 200 ml for 2 h incubation. Infections with a control vector rAd5CAG-LacZ were also performed at an MOI of 30 PFU/cell in a volume of 200 ml for 2 h incubation.
Antibodies
We used two mouse anti-human MRP-1/CD9 mAbs, M31-15 and ALB-6. M31-15 was developed in our laboratory (Miyake et al., 1991) . ALB-6, a neutralizing mAb, was purchased from Immunotech (Marseille, France). Mouse anti-human actin mAb (C-2), rabbit anti-human Wnt1 polyclonal Ab (H-89), goat anti-human WISP-1 polyclonal Ab (N-19) , goat antihuman WISP-3 polyclonal Ab (N-18), mouse anti-c-Myc mAb (9E10), and rabbit anti-VEGF-A polyclonal Ab (A-20) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Secondary horseradish peroxidase (HRP)-labeled antimouse IgG Ab and HRP-labeled anti-rabbit IgG Ab were purchased from Amersham Pharmacia Biotech (Buckinghamshire, UK). HRP-labeled anti-goat IgG Ab was purchased from ICN Pharmaceuticals (Aurora, OH, USA).
Flow cytometric assay
In order to evaluate MRP-1/CD9 protein expression in each group of cells, we performed flow cytometric assays. At 3 days after treatment with each adenoviral vector, 2 Â 10 5 cells, one twentieth of the population maintained in 10 cm culture dishes, were placed into each tube on ice for immunofluorescence staining. Simultaneously, other subsequent experiments, including the extraction of total RNA, motility assay, invasion assay, and protein sample preparation for Western blot analysis, were performed using the remaining cells maintained in 10 cm culture dishes. Then, the cells placed into tubes for immunofluorescence staining were incubated with an antihuman MRP-1/CD9 mAb M31-15, for 1 h on ice. After being washed twice, cells were incubated with FITC-conjugated AffiniPure F(ab 0 ) 2 fragment anti-mouse IgG antibody (Immunotech, Marseille, France). Finally, the fluorescence intensity of the cells was measured on a EPICS XL flow cytometer (Beckman Coulter, Fullerton, CA, USA).
Motility assay and invasion assay
The motility assay was performed using Transwell plates (polycarbonate membrane, 8 mm pores; Costar, Cambridge, MA, USA). In all, 2 Â 10 5 cells were added to the top chamber and assays performed at 371C, 5% CO 2 , for 12 h for HT1080, for 48 h for A549. Cells passing through the membrane into the lower chamber were counted. For the invasion assay, Transwell plates were precoated on both sides with Matrigel (30 mg/well, Becton Dickinson Lab, Bedford, MA, USA). Then, 2 Â 10 5 cells were added to the top chamber and assays performed at 371C, 5% CO 2 . The membrane was fixed in methanol and stained with Giemsa. The upper side was wiped off, and cells that attached to the lower side were counted. Both in the motility assay and in the invasion assay, each condition was tested in triplicate per experiment, and each experiment repeated twice with consistent results. Data shown are the average7standard deviation of all six results combined.
Microarray assay
After an evaluation of MRP-1/CD9 protein expression by flow cytometric assay, total cellular RNA was extracted by the acid guanidinium thiocyanate procedure. Labeling of total RNA (20 mg/slide) was performed by incorporation of aminoallyldUTP (Ambion Inc., Austin, TX, USA) and subsequent coupling of monoreactive Cy3 and Cy5 (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA). Free dye was removed using a P30 column (BioRad Lab., Hercules, CA, USA). Then, the purified and concentrated dye-labeled cDNA solutions were hybridized to the AceGene slides (DNA Chip Research Inc., Yokohama, Japan) for 16 h at 451C. After the hybridization, the slides were washed, and then dried. Finally, AceGene slides were scanned in a ScanArray Lite (Perkin-Elmer Life Science, Fremont, CA, USA) and the resulting fluorescent signals quantified and stored. The hybridizations were performed in duplicate from independent RNA extractions.
Fluorescent signals were analysed using QuantArray (PerkinElmer Life Science). Normalization was performed as follows. At first, average signals of Cy3 and Cy5 in 'Background spots', which were the spotting solution only, were calculated as Cy3BG and Cy5BG, respectively. Then, 'Cy3-Cy3BG' and 'Cy5-Cy5BG' for each spot was obtained. Spots which showed (Cy3-Cy3BG) þ (Cy5-Cy5BG)41000 are classified as valid spots. (Cy3-Cy3BG)/(Cy5-Cy5BG) in each valid spot was obtained. The average of (Cy3-Cy3BG)/(Cy5-Cy5BG) in each valid spot was obtained as 'Global Average'. Then (Cy3-Cy3BG)/(Global Average) and (Cy5-Cy5BG) were calculated for each spot. Finally, the average ratio for each spot was calculated for duplicated samples. The ratio more than 2.0 or less than 0.5 was empirically considered to be significant.
Real-time quantitative RT-PCR
First-strand cDNA synthesis was performed with 5 mg of total RNA using a cDNA synthesis kit (Amersham) according to the manufacture's protocol. To qualify gene expression, TaqMan real-time quantitative PCR was performed with the ABI PRISM 7700 Sequence Detection Systems using Assays on-Demand Gene Expression probes and TaqMan Universal PCR Master Mix (Applied Biosystems). The PCR cycling conditions for all samples were as follows: 501C, 2 min for AmpErase UNG activation; 951C, 10 min for AmpliTaq Gold activation; and 40 cycles for the melting (951C, 15 s) and annealing/extension (601C, 1 min) steps. Each sample was run in triplicate, and each PCR experiment included three nontemplate control wells. In addition, triplicate assays were performed with RNA samples isolated from at least two independent experiments. A standard curve for serial dilutions of cDNA of control HT1080 or control A549 was similarly generated. The comparative threshold cycle method (Applied Biosystems) was used to calculate gene expression in each sample relative to the value observed in parental cells, control HT1080 and control A549, respectively, using GAPDH as a control for normalization among samples.
Western blot analysis
Western blot analysis was performed to evaluate the expression of various proteins. Briefly, cells were harvested and resuspended in lysis buffer (62.5 mM Tris-HCl, 2% SDS, 10% glycerol, 4 M urea). Protein samples (50 mg) were each diluted into a 20 ml solution of lysis buffer and 5% 2-mercaptoethanol (Bio-Rad) and heated in a water bath at 951C for 5 min. Then, protein extracts were separated by 10% SDS-PAGE in a vertical-slab gel electrophoresis cell (Bio-Rad). Next, the separated proteins were transferred from gel to nitrocellulose membrane (Hybond-ECL; Amarsham) and then blocked in a blocking solution (5% dry milk and 0.2% Tween 20 in PBS) for 1 h. Then, membranes were incubated with the primary antibodies M31-15 (1 : 100), Wnt1 (1 : 500), WISP-1 (1 : 500), WISP-3 (1 : 500), c-Myc (1 : 500), and VEGF-A (1 : 500). The membranes were then incubated with HRP-labeled secondary antibodies. The proteins were visualized on enhanced chemiluminescence film (Hyperfilm; Amersham) by application of Western Blotting Detection System (Amersham). Finally, the blots were reprobed using antibodies against actin (1 : 1000) to ensure equal loading and transfer of proteins.
